FierceBiotech 15 dic 2025 Beyond the ADC Hype: Innovation is accelerating through bispecifics and dual payload strategies
FierceBiotech 13 dic 2025 GAO probe finds understaffed FDA putting some medical device recall work on the 'back burner'
FierceBiotech 12 dic 2025 Obesity biotech Zealand seeks partners to ‘take therapies directly to the brain’
FierceBiotech 12 dic 2025 Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share
FierceBiotech 12 dic 2025 2026 outlook: Biotech poised to outperform bear markets of ’21-24, analyst says
FierceBiotech 11 dic 2025 Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx
FierceBiotech 11 dic 2025 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
FierceBiotech 11 dic 2025 Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test
FierceBiotech 11 dic 2025 FDA clears Lumosity brain training games as a prescription app for adult ADHD
FierceBiotech 11 dic 2025 Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech
FierceBiotech 11 dic 2025 Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs